Novartis announces tislelizumab efficacy results from phase 3 trial
Tislelizumab shows favourable safety profile compared to sorafenib among liver cancer patients
Read More
Tag: tislelizumab
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
- Gedeon Richter UK takes over UK rights to cariprazine
- Otsuka Pharmaceutical’s Dawnzera receives EC approval for hereditary angioedema prevention
